UBS Group’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $58.7K | Sell |
32,635
-10,725
| -25% | -$19.3K | ﹤0.01% | 6362 |
|
|
2025
Q1 | $82.8K | Buy |
43,360
+8,133
| +23% | +$15.5K | ﹤0.01% | 5918 |
|
|
2024
Q4 | $76.1K | Buy |
35,227
+26,772
| +317% | +$57.8K | ﹤0.01% | 5825 |
|
|
2024
Q3 | $15.1K | Sell |
8,455
-2,967
| -26% | -$5.28K | ﹤0.01% | 6316 |
|
|
2024
Q2 | $14.6K | Buy |
11,422
+2,749
| +32% | +$3.52K | ﹤0.01% | 6349 |
|
|
2024
Q1 | $32.7K | Sell |
8,673
-5,350
| -38% | -$20.2K | ﹤0.01% | 5528 |
|
|
2023
Q4 | $45.8K | Buy |
14,023
+5,719
| +69% | +$18.7K | ﹤0.01% | 5384 |
|
|
2023
Q3 | $27.2K | Sell |
8,304
-1,143
| -12% | -$3.75K | ﹤0.01% | 5504 |
|
|
2023
Q2 | $42.3K | Buy |
9,447
+5,142
| +119% | +$23K | ﹤0.01% | 5505 |
|
|
2023
Q1 | $20.8K | Sell |
4,305
-2,984
| -41% | -$14.4K | ﹤0.01% | 5954 |
|
|
2022
Q4 | $22.8K | Buy |
7,289
+3,167
| +77% | +$9.91K | ﹤0.01% | 6340 |
|
|
2022
Q3 | $13K | Sell |
4,122
-2,289
| -36% | -$7.22K | ﹤0.01% | 6931 |
|
|
2022
Q2 | $23K | Buy |
6,411
+2,311
| +56% | +$8.29K | ﹤0.01% | 5667 |
|
|
2022
Q1 | $17K | Sell |
4,100
-6,397
| -61% | -$26.5K | ﹤0.01% | 6604 |
|
|
2021
Q4 | $57K | Buy |
10,497
+3,757
| +56% | +$20.4K | ﹤0.01% | 5687 |
|
|
2021
Q3 | $51K | Buy |
6,740
+2,640
| +64% | +$20K | ﹤0.01% | 5207 |
|
|
2021
Q2 | $41K | Sell |
4,100
-2,005
| -33% | -$20.1K | ﹤0.01% | 5540 |
|
|
2021
Q1 | $91K | Buy |
+6,105
| New | +$91K | ﹤0.01% | 5045 |
|